Skip to content

US · BBOT · BIOTECHNOLOGY

BridgeBio Oncology Therapeutics Inc. (BBOT) intrinsic value and stock valuation

$1.81as of 2026-11-21 · Mkt cap 717.76M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BridgeBio Oncology Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values BBOT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BBOT’s statements →

BridgeBio Oncology Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 bbotx.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-134.04M
20212025
Free cash flow
-$-114.5M
20212025
Total equity
$411.1M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-145.82M-$-80.86M-$-64.77M-$0.00-$-40K
Net income-$-134.04M-$-74.28M-$-64.7M-$0.00-$-40K
EPSd-$-4.3M-$-4.46M-$-3.16M-$0.00-$-1.95K
Operating cash flow-$-113.89M-$-760K-$-52.08M$0.00$0.00
Capital expenditure-$-610K$0.00$0.00$0.00$0.00
Free cash flow-$-114.5M-$-760K-$-52.49M$0.00$0.00
Total assets$448.4M$194.4M$330K$140K$140K
Total debt$2.77M$0.00$70K$40K$40K
Net debt-$-370.92M-$-1.7M$70K$40K$40K
Total equity$411.1M$188.7M-$-60K-$-20K-$-20K
Cash and short-term investments$425.5M$1.7M$0.00$0.00$0.00
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$121.2M$73.1M$56.3M$0.00$0.00
Selling, general and administrative expenses$24.6M$7.76M$8.48M$0.00$40K
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$145.8M$80.9M$64.8M$0.00$40K
Cost and expenses$145.8M$80.9M$64.8M$0.00$40K
Interest income$11.3M$8.46M$70K$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$610K$210K$90K$0.00$70K
Ebitda-$-145.21M-$-80.66M-$-64.68M-$0.00-$-40K
Operating income-$-145.82M-$-80.86M-$-64.77M-$0.00-$-40K
Total other income/expenses, net$11.8M$8.18M$70K$0.00$0.00
Income before tax-$-134.04M-$-74.28M-$-64.7M-$0.00-$-40K
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-134.04M-$-74.28M-$-64.7M-$0.00-$-40K
Weighted average shares outstanding$31.1M$16.6M$20.5M$20.5M$20.5M
Weighted average diluted shares outstanding$31.1M$16.6M$20.5M$20.5M$20.5M
Balance sheet
20252024202320222021
Cash and short-term investments$425.5M$1.7M$0.00$0.00$0.00
Net receivables$390K$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$425.5M$1.95M$0.00$0.00$0.00
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$130K$192.5M$0.00$0.00$0.00
Total non-current assets$22.9M$192.5M$330K$140K$140K
Total assets$448.4M$194.4M$330K$140K$140K
Accounts payable$1.37M$0.00$0.00$0.00$0.00
Short-term debt$520K$0.00$70K$40K$40K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$35M$190K$400K$170K$160K
Long-term debt$2.24M$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.24M$5.52M$0.00$0.00$0.00
Capital lease obligations$520K$0.00$0.00$0.00$0.00
Total liabilities$37.3M$5.71M$400K$170K$160K
Common stock$10K$192.5M$0.00$0.00$0.00
Retained earnings-$-356.57M-$-3.73M-$-90K-$-50K-$-40K
Accumulated other comprehensive income (loss)$20K$0.00$0.00$0.00$0.00
Total equity$411.1M$188.7M-$-60K-$-20K-$-20K
Total investments$51.9M$192.5M$0.00$0.00$0.00
Total debt$2.77M$0.00$70K$40K$40K
Net debt-$-370.92M-$-1.7M$70K$40K$40K
Cash flow statement
20252024202320222021
Net income-$-134.04M$7.6M-$-40K-$0.00-$0.00
Depreciation and amortization$610K$0.00$0.00$0.00$0.00
Stock-based compensation$5.87M$270K$0.00$0.00$0.00
Change in working capital$6.43M-$-100K$10K$0.00$0.00
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.84M$170K$0.00$0.00$0.00
Net cash provided by operating activities-$-113.89M-$-760K-$-52.08M$0.00$0.00
Investments in property, plant and equipment-$-610K$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$73.3M-$-184M$0.00$0.00$0.00
Common stock issued$395.7M$187.3M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$383.4M$186.5M$0.00$0.00$0.00
Net change in cash$342.8M$1.7M$230K$0.00$0.00
Cash at end of period$373.8M$1.7M$250K$0.00$0.00
Operating cash flow-$-113.89M-$-760K-$-52.08M$0.00$0.00
Capital expenditure-$-610K$0.00$0.00$0.00$0.00
Free cash flow-$-114.5M-$-760K-$-52.49M$0.00$0.00
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BridgeBio Oncology Therapeutics Inc.

        BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.

        CEO
        Pedro J. Beltran
        Employees
        92
        Beta
        0.39

        Explore

        Frequently asked questions

        What is the intrinsic value of BridgeBio Oncology Therapeutics Inc. (BBOT)?

        InvestorsCraft does not currently publish an intrinsic value for BBOT. How the IC value is calculated.

        Is BBOT undervalued?

        InvestorsCraft does not publish an undervaluation signal for BBOT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.